JCN Newswire
TOKYO, July 23, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, “KYORIN”) announced today that Eisai (Thailand) Marketing Co., Ltd. (“Eisai Thailand”), a subsidiary of Eisai, has launched overactive bladder treatment Beova® Tablets (generic name vibegron) in Thailand.In 2021…
Read More
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
Marquis Volkman
08:34
TOKYO, July 23, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, “KYORIN”) announced today that Eisai (Thailand) Marketing Co., Ltd. (“Eisai Thailand”), a subsidiary of Eisai, has launched overactive bladder treatment Beova® Tablets (generic name vibegron) in Thailand.In
